Products with Anti-hyperlipidemic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN6274 | Protodioscin |
| Protodioscin has been shown to exhibit multiple biological actions, such as anti-hyperlipidemia, anti-cancer, sexual effects and cardiovascular properties. It appears to possess aphrodisiac activity probably due to its androgen increasing property, it will be useful in developing health food supplement(s) and/or drug(s) against hyperlipidemia. | |
| BCN6312 | Naringin |
| Naringin exhibits antioxidant, anti-atherogenic, antiulcer, anti-hypocholesterolemic, anti-lipoperoxidative, and anti-hyperglycemia effects. Naringin reduces Ara-C-induced oxidative stress through both an inhibition of the generation of ROS production and an increase in antioxidant enzyme activities, it blocks apoptosis caused by Ara-C-induced oxidative stress, resulting in the inhibition of the cytotoxicity of Ara-C. Naringin attenuates epidermal growth factor (EGF)-induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs-AP-1 and IKKs-IκB-NF-κB signaling pathways. | |
| BCN6313 | Proanthocyanidins |
| Proanthocyanidins exerts antiviral, hepatoprotective, cardioprotective, hypolipidemic, anti-osteoporosis, anti-inflammatory ,antioxidant and anti-apoptosis activities. Dietary proanthocyanidins inhibits photocarcinogenesis in mice through the inhibition of UVB-induced inflammation and mediators of inflammation in mouse skin. Proanthocyanidins form stable complexes with metal ions and with proteins and are good reducing agents, they may participate in the prevention of cancers, both of the digestive tract and inner organs, they may also protect LDLs against oxidation and inhibit platelet aggregation and therefore prevent cardiovascular diseases. | |
| BCN6328 | (-)-Gallocatechin gallate |
| (-)-Gallocatechin gallate has cancer-preventive activities, it can precipitate cholesterol, decreasee osteoclastogenesis at 20 microM. | |
| BCN8446 | Mogrol |
| Mogrol has exhibited anti-cancer activities, it suppressed leukemia cell growth via inhibition of the ERK1/2 and STAT3 pathways, in particular, through the suppression of p-ERK1/2 and p-STAT3. Mogrol significantly improved LPS-induced memory impairment in mice. It also suppressed adipogenesis by reducing CREB activation in the initial stage of cell differentiation and by activating AMPK signaling in both the early and late stages of this process. | |
